Ask AI

Decera Clinical Education's Independent Conference Highlights From the 2026 ASCO Annual Meeting

Review Capsule Summaries and a certified expert-authored ClinicalThought commentary highlighting key studies from the 2026 ASCO annual meeting.

Share

Program Content

3 Capsule Summaries

Activities

RASolute 302
RASolute 302: Phase III Trial of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2026

FIGHT-302
FIGHT-302: Phase III Trial of Pemigatinib as First-line Treatment for Unresectable Advanced or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2026

EMERALD-3
EMERALD-3: Phase III Trial of Tremelimumab + Durvalumab ± Lenvatinib Combined With TACE in Unresectable Embolization-Eligible HCC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

This activity is supported by an educational grant from Incyte Corporation.

Incyte Corporation